BRCA1 and cholangiocarcinoma: The results of this trial, which are expected in 2021, and those from other trials are needed to clarify, firstly, the real role of BRCA1 and BRCA2 mutations in CCA, and secondly, the potential role for PARPi use either in monotherapy or in combination with other drugs.